Determinants of Compliance With Glaucoma Therapy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01484392|
Recruitment Status : Completed
First Posted : December 2, 2011
Last Update Posted : March 9, 2016
|Condition or disease|
|Open Angle Glaucoma|
|Study Type :||Observational|
|Actual Enrollment :||60 participants|
|Official Title:||Determinants of Compliance With Glaucoma Therapy|
|Study Start Date :||August 2006|
|Actual Primary Completion Date :||December 2013|
|Actual Study Completion Date :||December 2013|
- Compliance with glaucoma medication at 1 month [ Time Frame: 1 month after enrollment ]Compliance is measured using the Travatan Dosing Aid, a device that records when patients administer their topical glaucoma medication.
- Compliance with glaucoma medication at 3 months [ Time Frame: 3 months after enrollment ]Compliance is measured using the Travatan Dosing Aid, a device that records when patients administer their topical glaucoma medication.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01484392
|United States, Oregon|
|Devers Eye Institute|
|Portland, Oregon, United States, 97210|
|Principal Investigator:||Steven L Mansberger, MD, MPH||Legacy Health|